J Menopausal Med.  2016 Aug;22(2):71-75. 10.6118/jmm.2016.22.2.71.

Cell Therapy Products in Menopausal Medicine

• Choi HJ
• Kim TH
• Kim SA
• Kim JM
• Lee A
• Song HJ
• Park YJ

• KMID: 2365461
• DOI: http://doi.org/10.6118/jmm.2016.22.2.71

Abstract

The incidence of postmenopausal diseases increases with the age of women. In this review, we introduce cell therapy products, a new treatment for postmenopausal osteoporosis, which often occurs in postmenopausal women. We also figure out the trends of research on cell therapy products and emphasize the necessity and importance of this research for researchers and postmenopausal women. Finally, we suggest the direction for improvement of postmenopausal osteoporosis and research on cell therapy products. We investigated which medication have been used so far. We also examined the development and technical problems of technologies that are currently in use.

Keyword

Cell- and tissue-based therapy; Menopause; Osteoporosis, postmenopausal; Stem cells

MeSH Terms

Cell- and Tissue-Based Therapy*
Female
Humans
Incidence
Menopause
Osteoporosis, Postmenopausal
Stem Cells

Reference

1. Kwak EK, Park HS, Kang NM. Menopause knowledge, attitude, symptom and management among midlife employed women. J Menopausal Med. 2014; 20:118–125.

2. Chun S. The relationship of hot flush to other menopausal symptoms and chronic disease related to menopause. J Korean Soc Menopause. 2013; 19:54–63.

3. Koo YH, Song YJ, Na YJ. Mortality associated with hormone replacement therapy in postmenopausal women. J Korean Soc Menopause. 2012; 18:133–138.

4. Kim TH, Lee HH, Chung SH, Park HS. Differentiation in the management of osteoporosis between premenopausal and menopausal women. J Korean Soc Menopause. 2011; 17:21–26.

5. Bock O, Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice. Clin Interv Aging. 2008; 3:279–297.

6. Chang YH, Liu HW, Wu KC, Ding DC. Mesenchymal stem cells and their clinical applications in osteoarthritis. Cell Transplant. 2016; 25:937–950.

7. Lee SY, Yang JW, Jung JS. Role of NFAT5 in osteogenic differentiation of human adipose tissue-derived mesenchymal stem cells. J Life Sci. 2013; 23:471–478.

8. Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S, Morelli V, et al. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis. Osteoporos Int. 2014; 25:1401–1410.

9. Lee HM, Joo BS, Lee CH, Kim HY, Ock JH, Lee YS. Effect of glucagon-like peptide-1 on the differentiation of adipose-derived stem cells into osteoblasts and adipocytes. J Menopausal Med. 2015; 21:93–103.

10. Thummuri D, Jeengar MK, Shrivastava S, Nemani H, Ramavat RN, Chaudhari P, et al. Thymoquinone prevents RANKL-induced osteoclastogenesis activation and osteolysis in an in vivo model of inflammation by suppressing NF-KB and MAPK Signalling. Pharmacol Res. 2015; 99:63–73.

11. Tompkins KA. The osteoimmunology of alveolar bone loss. Connect Tissue Res. 2016; 57:69–90.

12. Alm JJ, Heino TJ, Hentunen TA, Väänänen HK, Aro HT. Transient 100 nM dexamethasone treatment reduces inter- and intraindividual variations in osteoblastic differentiation of bone marrow-derived human mesenchymal stem cells. Tissue Eng Part C Methods. 2012; 18:658–666.

13. Park S, Kang HM, Heo J, Yoon J, Kim H. Characterization of umbilical cord-derived stem cells during expansion in vitro. Korean J Reprod Med. 2009; 36:23–34.

14. Park MS, Kim YH, Jung Y, Kim SH, Park JC, Yoon DS, et al. In situ recruitment of human bone marrow-derived mesenchymal stem cells using chemokines for articular cartilage regeneration. Cell Transplant. 2015; 24:1067–1083.

15. Held LA, Rizzieri D, Long GD, Gockerman JP, Diehl LF, de Castro CM, et al. A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma. Cancer Invest. 2013; 31:172–176.

16. Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. Leuk Lymphoma. 2013; 54:555–560.

17. Kim MY, Choi SD, Ryu A. Is complementary and alternative therapy effective for women in the climacteric period? J Menopausal Med. 2015; 21:28–35.

18. Jeong EH, Hong GY, Kim BR, Park SN, Lee HH, Na YJ, et al. The relationship between uterine myoma growth and the endocrine disruptor in postmenopausal women. J Menopausal Med. 2013; 19:130–134.

19. Jeon DS, Kim TH, Lee HH, Byun DW. Endometriosis in a postmenopausal woman on hormonal replacement therapy. J Menopausal Med. 2013; 19:151–153.